Anton Rx Report

This week the FDA approved a new ORAL therapy, Ukoniq (umbralisib) from TG Therapeutics with indications for marginal zone lymphoma (MZL) and follicular lymphoma (FL).

Specialty pharmacies won’t be dispensing Breyanzi, approved by the FDA last week for the treatment of late-stage lymphoma with certain types of large B-cell lymphoma

During 2020 we saw a measurable uptick in the number of FDA approved therapies that were LD-DTO….. which you should know stands for Limited Distribution,

The FDA has approved a new, first ever therapy for Lupus nephritis, Lupkynis (voclosporin) from Aurinia Pharmaceuticals, in combination with background immunosuppressive therapy. It is

The 340b program is once again in the news. All the wailing and gnashing of teeth over recent years boiled over on 2020 with a

Last week the FDA approved a new specialty therapy for adult HIV positive patients. Be patient, it will take some time to explain this announcement

An acquisition that has material implications for the specialty pharmacy industry was announced last week. Shields Health Solutions acquired ExceleraRx for an undisclosed amount. Like

The FDA actually did a remarkable job in 2020 approving new drugs. In spite of the pandemic they managed to approve 53 novel drugs. That’s

WOW….. Centene is ponying up $2.2 billion to acquire Magellan Health! This comes on the heels of Centene’s recently announced acquisition of PANTHER Rx only

We recently sent an RxReport detailing the FDA approval of Orgovyx as the last FDA approval in 2021. That was technically correct….. but there is